Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

被引：0
|
作者：
Ahmad, Suhana [1 ]
Lambuk, Lidawani [1 ]
Ahmed, Naveed [2 ]
Mussa, Ali [3 ,4 ]
Tee, Vincent [5 ]
Idris, Ros Akmal Mohd [1 ]
Sahran, Nur Fazimah [5 ]
Chan, Yean Yean [2 ]
Hassan, Rosline [3 ]
Lee, Yeong Yeh [5 ,6 ]
Mohamud, Rohimah [1 ]
机构：
[1] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia
[2] Univ Sains Malaysia, Sch Med Sci, Dept Med Microbiol & Parasitol, Kubang Kerian 16150, Kelantan, Malaysia
[3] Univ Sains Malaysia, Sch Med Sci, Dept Haematol, Kubang Kerian 16150, Kelantan, Malaysia
[4] Omdurman Islamic Univ, Dept Biol, Omdurman 14415, Sudan
[5] Univ Sains Malaysia, Sch Med Sci, Dept Internal Med, Kubang Kerian 16150, Kelantan, Malaysia
[6] Univ Sains Malaysia, Hosp Univ Sains Malaysia, GI Funct & Motil Unit, Kubang Kerian 16150, Kelantan, Malaysia
来源：
NANOMEDICINE | 2023年 / 18卷 / 24期
关键词：
chemotherapy; nanomedicine; nanoparticle; response rate survival; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; PHASE-II; CHEMOTHERAPY; RAMUCIRUMAB; COMBINATION;
D O I：
10.2217/nnm-2022-0300
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel. A systematic review and meta-analysis estimates the efficacy and safety of nab-paclitaxel in metastatic gastric cancer.
引用
收藏
页码：1733 / 1744
页数：12
相关论文
共 50 条
  • [21] Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals
    Hashida, Shinsuke
    Tanaka, Norimitsu
    Takahashi, Yuta
    Onoda, Yuji
    Colvin, Hugh Shunsuke
    Ohashi, Ryuichiro
    Okamoto, Kunio
    ACTA MEDICA OKAYAMA, 2021, 75 (02) : 133 - 138
  • [22] Retrospective Analysis of the Relative Efficacy and Toxicity of Nab-paclitaxel and Docetaxel in Metastatic Breast Cancer
    Howell, S. J.
    Armstrong, A. C.
    Ashcroft, L.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S115 - S116
  • [23] Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis
    Zhang, Y.
    Shi, S.
    Yu, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
    Lee, Yoon Suk
    Lee, Jong-chan
    Kim, Jae-Hyeong
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis
    Peng, L.
    Bu, Z.
    Ye, X.
    Zhou, Y.
    Zhao, Q.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (05)
  • [26] Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
    Yoon Suk Lee
    Jong-chan Lee
    Jae-Hyeong Kim
    Jaihwan Kim
    Jin-Hyeok Hwang
    Scientific Reports, 11
  • [27] Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer-Reply
    Funada, Satoshi
    Yoshioka, Takashi
    Luo, Yan
    JAMA ONCOLOGY, 2021, 7 (04) : 634 - +
  • [28] Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
    Rapposelli, Ilario Giovanni
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Bartolini, Giulia
    Bernardini, Laura
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Massa, Valentina
    Cucchetti, Alessandro
    BIOMOLECULES, 2021, 11 (06)
  • [29] Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
    Wan, Rui
    Guo, Yanrong
    Hao, Xuezhi
    Wang, Zhijie
    Duan, Jianchun
    Wang, Jie
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [30] A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
    Kim, Jung Sun
    Suh, Koung Jin
    Lee, Dae-Won
    Woo, Go-Un
    Kim, Miso
    Kim, Se Hyun
    Ryu, Han Suk
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Han, Sae-Won
    Park, So Yeon
    Park, In Ae
    Kim, Jee Hyun
    Im, Seock-Ah
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 488 - 496
12345